Skip to main content

Full text of "USPTO Patents Application 10643431"

See other formats


OLDHAM, et ax 



64 



DX0934K1 



WHAT IS CLAIMED IS: 

1. .A method of modulating migration of a cell within 
or to the skin of a mammal, said method comprising 

5 administering to said mammal an effective amount of : 

a) an antagonist of MIP-3a,- 

b) an agonist of MIP-3CX; 

c) an antagonist of CCR6; or 

d) an agonist of CCR6 . 

10 

2. The method of Claim 1, wherein said migration is 
within said skin. 

3. The method of Claim 2, wherein said migration is 
15 chemotactic or chemokinetic . 

4. The method of Claim 1, wherein said administering 
is systemic, local, topical, subcutaneous, intracutaneous, 
or transdermal . 

20 

5. The method of Claim 1, wherein said cell is a T 
cell, B cell, dendritic cell, or dendritic cell precursor. 

6. The method of Claim 5, wherein said cell is a T 
25 cell. 

7. The method of Claim 1, wherein said cell migrates 
into the dermal and/or epidermal layers of said skin. 

30 8. The method of Claim 1, wherein said administering 

is an antagonist of MIP-3oc. 

9. The method of Claim 8, wherein said antagonist is 

selected from: 
35 a) a mutein of natural MIP-3a; 

b) an antibody which neutralizes MIP-3ct; or 

c) an antibody which binds to CCR6 . 



OLDHAM, et al 



65 



DX0934K1 



10. The method of Claim 8, wherein said mammal is 
subject to a skin condition, including one selected from 
cancer, cancer metastasis, autoimmunity, inflamation, 

5 infection, psoriasis, skin transplant, or skin graft. 

11. The method of Claim 8, wherein said antagonist is 
administered in combination with an antibiotic, antifungal, 
antiviral, cancer therapy, or analgesic. 

10 

12. The method of Claim 8, wherein said antagonist is 
administered in combination with an immune suppressive 
therapeutic, ant i -inflammatory drug, growth factor, or 
immune adjuvant. 

15 

13. The method of Claim 1, wherein said administering 
is with a primate MIP-3cc. 

14. The method of Claim 13, wherein said modulating 
20 is attracting said cell. 

15. The method of Claim 14, wherein said cell is 
attracted to a site of cutaneous lesion. 

25 16. The method of Claim 13, wherein said primate MIP- 

3a is administered in combination with an antibiotic, 
antifungal, antiviral, or analgesic. 

17. The method of Claim 13, wherein said MIP-3a is 
30 administered in combination with a vasodilator, growth 

factor, cytokine, anti-inflammatory drug, or immune 
adjuvant . 

18. A method of purifying a population of cells, said 
35 method comprising contacting said cells with MIP-30C, 

thereby resulting in the identification of cells expressing 
a receptor for said MIP-3cc. 



OLDHAM, et al. 66 DX0934K1 



19. The method of Claim 18, wherein: 

a) said receptor is CCR6; or 

b) said contacting results in specific migration of 

said cells to a site for purification. 



20. The method of Claim 18, wherein said migration is 

through pores of a membrane.